 |
In the pharma industry, speed is of the essence. The Patheon OneSource™ model exemplifies the benefits of an end-to-end supply chain for pharma and biopharma clients by accelerating time to clinic and to market, adding cost savings, and putting formulations on the path to regulatory success. Following a CPhI North America panel on single-vendor CDMOs, PharmTech spoke with Anil Kane, PhD, executive director and global head of technical and scientific affairs at Patheon, to talk about his views on the subject. |
|
